Influenza A virus H5N1 hemagglutinin (H5N1 HA)

Influenza A virus H5N1 hemagglutinin is a trimeric viral surface glycoprotein crucial for the infectivity and host specificity of the H5N1 influenza virus[3][4][5][6][7]. It functions by specifically binding to sialic acid receptors on the surface of host cells (primarily in the respiratory tract), which enables virus attachment and entry. After endocytosis, hemagglutinin mediates the fusion of the viral and endosomal membranes in response to acidic pH, allowing the viral genome to enter the host cell cytoplasm[3][4]. Hemagglutinin is the principal target of neutralizing antibodies generated during infection or vaccination, making it a primary focus for antiviral therapies, vaccine design, and surveillance. The molecule is highly variable, with frequently mutating antigenic sites, but also contains conserved regions that are desirable for broad-spectrum antibody and drug development[1][4][5]. The protein exists in multiple subtypes; H5N1 refers to subtype 5 of type 1 neuraminidase (N1). Structural studies have delineated conserved and variable antigenic sites, and recent research has described novel inhibitors and antibody-binding “vulnerable sites” on the H5N1 hemagglutinin head and stem domains[1][6]. Due to its crucial role in viral entry and pathogenicity, H5N1 hemagglutinin is considered a canonical therapeutic target for influenza antivirals and immunotherapeutics[1][4][6].

Other names

Hemagglutinin H5H5 hemagglutininHAH5N1 HA protein

Inhibition of receptor binding Inhibition of membrane fusion Neutralization by antibodies against conserved epitopes on HA[1][6]